Aminopyrazine derivatives as PI3K-γ inhibitors

US12421197B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Brent Douty · Coatesville, US
• Yanran Ai · West Chester, US
• David M. Burns · Woodbury, US
• Andrew P. Combs · Kennett Square, US
• Nikoo Falahatpisheh · Wilmington, US
• Daniel Levy · San Mateo, US
• Padmaja Polam · Kennett Square, US
• Lixin Shao · Wilmington, US
• Stacey Shepard · Wilmington, US
• Artem Shvartsbart · Kennett Square, US
• Eddy W. Yue · Landenberg, US
• Andrew W. Buesking · Wilmington, US

Key dates

• Filing date: May 24, 2021
• Grant date: Sep 23, 2025
• Expiry date: Jun 16, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F5/025
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.